Brigette B. Y. Ma, Stephen L. Chan, Wing M. Ho, Wilson Lau, Frankie Mo, Edwin P. Hui, Charles Chan, Annette Poon, Rasalkar D. Dattatray, S. C. Cesar Wong, Ka F. To, Ann D. King, Anil Ahuja and Anthony T. C. Chan Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer Cancer 119
Version of Record online: 1 OCT 2013 | DOI: 10.1002/cncr.28327
This phase 2 study is the first to evaluate the biological effect of different schedules of erlotinib in metastatic colorectal cancer. This study also demonstrates the prognostic utility of serum epidermal growth factor receptor ligands in erlotinib-treated patients with colorectal cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field